GLP-1 medications and thyroid cancer: what the evidence actually shows

TL;DR

The Clayman Thyroid Center - the highest-volume thyroid cancer referral practice in the United States, treating approximately 2,000 thyroid cancer patients annually - published a white paper in February 2026 finding zero convincing human evidence that GLP-1 medications cause papillary, follicular, or oncocytic thyroid cancer. The FDA black-box warning applies specifically and only to rare medullary thyroid carcinoma, which accounts for less than 5% of all thyroid cancers.

The warning label on Ozempic, Wegovy, and Mounjaro includes a black-box warning about thyroid cancer. For millions of people on these medications - and millions more considering them - that warning is a source of genuine anxiety. What does it actually mean? The answer requires separating two very different things: the cancer the warning is about, and the cancers most people are afraid of.

Understanding the FDA black-box warning

The FDA black-box warning on all GLP-1 receptor agonists states that the drug class may cause thyroid C-cell tumours, including medullary thyroid carcinoma (MTC). This warning was triggered by rodent studies showing that GLP-1 receptor activation caused C-cell hyperplasia (abnormal C-cell growth) and MTC in rats and mice at doses proportional to human therapeutic use.

Medullary thyroid carcinoma is a cancer of the C-cells - the cells in the thyroid that produce calcitonin. C-cells express GLP-1 receptors in rodents. The concern was that chronic GLP-1 receptor agonism might stimulate these cells and eventually trigger malignant transformation.

MTC accounts for roughly 3-5% of all thyroid cancers. It is a genuinely serious cancer, with distinct genetic profiles (about 25% are hereditary, linked to RET gene mutations) and a different natural history from the common types. The contraindication on GLP-1 medications is clear: these drugs should not be used by anyone with a personal or family history of MTC, or anyone with Multiple Endocrine Neoplasia type 2 (MEN2).

What the Clayman Thyroid Center found in humans

The Clayman Thyroid Center - which performs among the highest volumes of thyroid cancer surgeries globally and treats approximately 2,000 patients per year - conducted a comprehensive review of human evidence in early 2026. Their conclusion, published as a white paper in February 2026:

There is no convincing human evidence that GLP-1 medications cause papillary, follicular, or oncocytic thyroid cancers - the types that make up more than 95% of all thyroid cancer diagnoses.

The lead author, Dr. Gary Clayman, put it directly: "The FDA boxed warning is specific to a rare cancer called medullary thyroid carcinoma. It does not apply to the common thyroid cancers that account for more than 95 percent of cases."

The detection bias problem

When researchers observe that thyroid cancer diagnoses rise shortly after starting a medication, there are two possible explanations: the drug caused the cancer, or increased medical monitoring found cancers that were already there. This is called detection bias.

GLP-1 users receive more frequent medical contact - regular prescribing visits, blood work, and in many cases, neck imaging for other reasons. Any cancer incidentally detected in this more-monitored population will appear as a drug-associated cancer in epidemiological data, even if it pre-existed treatment. Co-author Dr. Rashmi Roy noted: "When diagnoses rise shortly after starting a medication, that pattern often reflects finding something that was already there."

Large population studies that have controlled for detection bias have not found increased thyroid cancer rates among GLP-1 users. This is a meaningful negative finding from studies designed to detect a real signal if it existed.

The rodent-to-human translation problem

The original safety concern came from rat and mouse studies. The Clayman Center's white paper addresses this directly: there are important biological differences between rodent and human thyroid C-cells that limit how much the animal data should inform human risk assessment.

Rodent C-cells have a much higher density of GLP-1 receptors than human C-cells. Rodents also have C-cells distributed throughout a larger proportion of their thyroid than humans. The doses used in rodent studies, when corrected for body surface area, were substantially higher than standard human therapeutic doses. The specific mechanism by which GLP-1 agonism caused C-cell tumours in rodents has not been demonstrated in human C-cells at clinically relevant receptor expression levels.

None of this means the warning should be disregarded - the FDA correctly requires a black-box warning when credible animal evidence exists, even without confirmed human cases. But it does explain why the world's largest thyroid cancer centre has not seen a surge in MTC cases linked to GLP-1 use.

Who should genuinely avoid GLP-1 medications on thyroid grounds

Two groups have clear contraindications:

• Anyone with a personal or family history of medullary thyroid carcinoma
• Anyone with Multiple Endocrine Neoplasia type 2 (MEN2) - a hereditary syndrome that includes a very high risk of MTC

If you do not fall into these categories, the thyroid cancer warning on your GLP-1 medication applies to a cancer type that has not been shown to occur at higher rates in human patients on these drugs. The common thyroid cancers - papillary, follicular, and Hürthle cell carcinoma - have no established causal link to GLP-1 medications in human data.

What this means for informed decision-making

Fear of cancer is a common reason people hesitate to start or continue GLP-1 therapy. For the overwhelming majority of patients, the thyroid cancer risk from GLP-1 medications is not a meaningful clinical concern beyond the standard MEN2/MTC contraindication screening. The cardiovascular, metabolic, and weight management benefits of GLP-1 medications are well-established and large. Weighing those against a hypothetical risk based on rodent data - that has not materialised in human surveillance data from the world's highest-volume thyroid cancer centres - is a decision that should be informed by the actual evidence.

If you have been on GLP-1 medications for weight loss or diabetes management and have no personal or family history of MTC or MEN2, the thyroid cancer warning does not change your risk calculus in any practical way. Focusing instead on the documented nutrient gaps that GLP-1 medications create - and addressing those proactively with targeted supplementation - is a more evidence-grounded priority. GLP-1 Shield exists to fill those gaps.

Frequently asked questions

Does Ozempic cause thyroid cancer?

The FDA black-box warning on GLP-1 medications applies specifically to medullary thyroid carcinoma (MTC) - a rare cancer type accounting for 3-5% of all thyroid cancers. The Clayman Thyroid Center, which treats 2,000 thyroid cancer patients per year, found no convincing human evidence that GLP-1 medications cause the common thyroid cancers (papillary, follicular, oncocytic) that account for over 95% of diagnoses. Large population studies controlling for detection bias have not found elevated thyroid cancer rates in GLP-1 users.

Who should not take GLP-1 medications because of thyroid risk?

GLP-1 medications are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma, and anyone with Multiple Endocrine Neoplasia type 2 (MEN2). These are rare conditions. People without these specific risk factors do not have a documented elevated thyroid cancer risk from GLP-1 use based on current human evidence.

Why does the Ozempic label have a black-box thyroid warning if the risk isn't proven in humans?

The FDA requires black-box warnings when credible animal studies show a risk, even if the same effect has not been observed in humans. GLP-1 medications caused C-cell tumours (including medullary carcinoma) in rats and mice. However, rodent C-cells have much higher GLP-1 receptor density than human C-cells, and the rodent doses were disproportionately high. The warning reflects regulatory caution with animal data, not confirmed human risk.

Should I be worried about thyroid cancer if I take Wegovy or Mounjaro?

If you have no personal or family history of medullary thyroid carcinoma or MEN2, the thyroid cancer warning on your GLP-1 medication does not represent a meaningful practical risk based on current human evidence. The world's largest thyroid cancer treatment centre has not observed a GLP-1-linked surge in common thyroid cancers. Your prescriber should screen for MTC/MEN2 risk factors before starting GLP-1 therapy - if they cleared you for the medication, the standard contraindication check has been done.